Navigation Links
Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
Date:4/16/2008

taxel at its maximum tolerated dose. In addition, preclinical studies involving a drug conjugate of paclitaxel and gemcitabine co-formulated into nanoparticles showed that a synergistic ratio of the two drugs circulating in plasma was maintained for more than 24 hours after intravenous injection.

"Historically, we have applied our technology to approved and widely used anti-cancer drugs using liposomes. By expanding our formulation platform to include nanoparticles for hydrophobic drugs, we now have greater flexibility in delivering synergistic drug combinations with widely varying chemical properties, potentially leading to more product opportunities," said Andrew Janoff, Ph.D., CEO of Celator. "Our goal is to substantially improve clinical outcomes offered by current combination drug therapies."

About Celator

Celator Pharmaceuticals, Inc., is a privately held pharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex(TM), the company's drug ratio technology platform, represents a revolutionary new approach that identifies a ratio of drugs that will deliver a synergistic benefit, locks the desired ratio in a drug delivery vehicle, and maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in a Phase 2 trial in patients with colorectal cancer; CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in a Phase 1 trial in patients with leukemia; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at http://www.celatorpharma
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014  Cepheid (NASDAQ: CPHD ) today ... conferences, and invited investors to participate via webcast. ... New York, NY Wednesday, August 13, 2014 at ... Conference, New York, NY Thursday, September ... Accessing Live Webcasts To access the live webcasts for these ...
(Date:7/31/2014)... Fla. , July 31, 2014 Rock ... today that it has initiated the development of its ... ; and that it has selected Quotient Clinical, The ... Kingdom (UK) to run its early development ... Clinical Trial Application (CTA) by the end of the ...
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, ... novel interventional devices to facilitate removal of blood clots, ... from the financing will support EU commercialization of several ... for the Lazarus ReCover™ and Lazarus Cover™ in ... financing reflects investor confidence in the value of our ...
Breaking Medicine Technology:Cepheid to Webcast Upcoming Financial Presentations 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Lazarus Effect Closes $5 Million Financing 2
(Date:7/31/2014)... 2014) If you have asthma, you may have an ... you recognize and respond to changes and understand when symptoms ... the green zone, you,re doing well, yellow means your asthma ... require urgent care. New guidelines are now available to help ... into green and away from the red zone. , "Management ...
(Date:7/31/2014)... GA (PRWEB) July 31, 2014 Developer ... camera on its Ponce City Market project in ... historic Sears, Roebuck & Company building into best-in-class office, ... completion, OxBlue reviewed Jamestown’s experience with their construction webcam ... , Jamestown wanted a construction camera ...
(Date:7/31/2014)... 31, 2014 Hoping to attract new customers ... trust , NutriGold is ready to ship out free ... make taking advantage of this offer fast and easy: ... and Development at NutriGold, "We know that every time customers ... their most precious asset: their own health or the health ...
(Date:7/31/2014)... Ce-Classes.com has announced that they are now offering a ... Systematic Review of Sexual Satisfaction . The course ... of Clinical and Health Psychology. , This CE course ... have accurate information about sexual satisfaction so that healthcare ... material provides a systematic review of 197 research publications ...
(Date:7/31/2014)... Dr. Stewart Shofner of Shofner Vision ... in the United States to successfully treat glaucoma by performing ... device ever approved by the FDA. Dr. Shofner is ... of using a procedure known as Selective Laser Trabeculoplasty (SLT) ... colleagues now recognize that this procedure is a primary treatment ...
Breaking Medicine News(10 mins):Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:NutriGold Launches Product Samples Page for its Supplements 2Health News:NutriGold Launches Product Samples Page for its Supplements 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 2Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 3Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 4
... Inc. (OTC Bulletin Board: CARN) today said the ... be webcast live from the Kennedy I Room ... Healthcare Conference at New York City,s Palace Hotel ... The presentation will cover DelSite,s three key ...
... CAMBRIDGE, Mass., Nov. 5 Abt Associates has ... Office of Planning, Research,and Evaluation within the U.S. ... and Families (ACF) to lead a major evaluation,of ... and former recipients of Temporary Assistance for Needy ...
... Care Awareness Week, WASHINGTON, Nov. 5 ... coverage for long-term care expenses,according to new survey ... The survey found that many Baby Boomers have ... have not thought about,long-term care insurance. (Logo: ...
... Relaxation in large, sound- and light-proof tanks with ... stress-related pain. This has been shown by Sven-ke ... with a dissertation from Karlstad University in Sweden. ... have indicated: sleep was improved, patients felt more ...
... may be more accurate than existing biological signposts ... into advanced forms of the disease. , ... edition of the International Journal of Cancer, the ... prevent patients from unnecessarily undergoing aggressive cancer treatments. ...
... /Xinhua-PRNewswire-FirstCall/ -- China Holdings, Inc.,(OTC Bulletin Board: ... its subsidiaries engage in multiple China-focused business ... real,estate, and pharmaceuticals, announced today the Company ... exclusive rights to develop and construct,the 2nd ...
Cached Medicine News:Health News:Carrington's DelSite Presentation at Rodman & Renshaw Conference to be Webcast Live on November 7th 2Health News:Abt Associates to Lead Major Evaluation of Programs Aimed at Promoting Self-Sufficiency for Disadvantaged Families 2Health News:New Survey Finds One in Four Baby Boomers Erroneously Believe They Have Coverage for Long-Term Care Expenses 2Health News:New Survey Finds One in Four Baby Boomers Erroneously Believe They Have Coverage for Long-Term Care Expenses 3Health News:Floating effective for stress and pain 2Health News:Biomarker may be an early predictor of advanced breast cancer 2Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 2Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 3Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 4Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 5Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 6Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 7Health News:China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline 8
CUSA DISSECTRON PORTABLE UNIT is an ultrasonic surgical aspirator for the fragmentation and emulsification of tissue available only outside the United States....
The Nevyas Drape Support is the simple and inexpensive way to establish a zone of comfort for your patients during ophthalmic surgery which requires draping over the nose and mouth. Packaged in sets ...
This is a 2.5x focusing Galilean telescope with a range from 70cm to infinity. Ideal for use at sporting events, as well as for a wide range of hobbies....
... us to the practical limit of ... often a 'last resort' option for ... The illuminated housing ensures a constant ... battery handle by a lightweight cord ...
Medicine Products: